Clinical Research Directory
Browse clinical research sites, groups, and studies.
ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer
Sponsor: Massachusetts General Hospital
Summary
This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy. This research study involves the collection of data and biospecimens (blood and tissue) to see if the presence of circulating tumor DNA (genetic material) ctDNA will help monitor rectal cancer more closely and potentially detect a recurrence before routine scans, performed per standard of care C2i Genomics, a biotechnology company, and the Spier Foundation are supporting this research study by providing funding for the study.
Official title: A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation or Pathologic Complete Response After Neoadjuvant Therapy for Rectal Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2023-01
Completion Date
2030-06
Last Updated
2022-11-29
Healthy Volunteers
No
Interventions
ctDNA
initial research biopsy, quality of life assessments and ctDNA collection
Locations (2)
Massachusetts General Hospital
Boston, Massachusetts, United States
Mass General Cancer Center Newton-Wellesley Hospital
Newton, Massachusetts, United States